Warning: The NCBI web site requires JavaScript to function. more...
Second Department of Obstetrics and Gynecology, University of Athens, Areteion University Hospital, Athens, Greece.
In this paper, we present a case of myxoid leiomyosarcoma development in a patient receiving tamoxifen for 3 years because of breast cancer. The myxoid leiomyosarcoma should be included in the differential diagnosis of any uterine tumor with a predominantly myxomatous composition. A review of the literature indicates that tamoxifen may increase not only the risk for endometrial cancer but also for uterine sarcoma, suggesting vigilance for uterine cancer in women who are being treated with this drug.
Your browsing activity is empty.
Activity recording is turned off.
Turn recording back on